Fyarro Now Available for Malignant Perivascular Epithelioid Cell Tumor
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Sarcoma
November 2021: 5 Notable Drug Approvals
The new approvals include Besremi, Fyarro, Livtencity, Voxzogo, and Vuity.
Fyarro Approved for Malignant Perivascular Epithelioid Cell Tumor
The approval of Fyarro, an mTOR inhibitor, was based on data from the phase 2 AMPECT study, which included 34 adults with advanced malignant PEComa.
Nanoparticle Albumin-Bound mTOR Inhibitor Gets Priority Review for Ultra-Rare Sarcoma
Nab-sirolimus is an mTOR inhibitor bound to human albumin.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
